BRPI0913485A2 - medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. - Google Patents

medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Info

Publication number
BRPI0913485A2
BRPI0913485A2 BRPI0913485A BRPI0913485A BRPI0913485A2 BR PI0913485 A2 BRPI0913485 A2 BR PI0913485A2 BR PI0913485 A BRPI0913485 A BR PI0913485A BR PI0913485 A BRPI0913485 A BR PI0913485A BR PI0913485 A2 BRPI0913485 A2 BR PI0913485A2
Authority
BR
Brazil
Prior art keywords
cancers
malignant melanoma
metastatic malignant
related uses
anticancer medicines
Prior art date
Application number
BRPI0913485A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhupathiraju Kiran
Gokaraju Ganga Raju
Gokaraju Rama Raju
Golakoti Trimurtulu
Kasina Sudhakar
Krishanu Sengupta
Somepalli Venkateswarlu
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of BRPI0913485A2 publication Critical patent/BRPI0913485A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0913485A 2008-09-15 2009-09-14 medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. BRPI0913485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
BRPI0913485A2 true BRPI0913485A2 (pt) 2016-06-07

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913485A BRPI0913485A2 (pt) 2008-09-15 2009-09-14 medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Country Status (11)

Country Link
US (1) US8258119B2 (https=)
EP (1) EP2324006B1 (https=)
JP (1) JP2012502900A (https=)
KR (1) KR20110063537A (https=)
CN (1) CN102149703B (https=)
AU (1) AU2009290365B2 (https=)
BR (1) BRPI0913485A2 (https=)
CA (1) CA2736732A1 (https=)
IL (1) IL211366A0 (https=)
NZ (1) NZ591394A (https=)
WO (1) WO2010029577A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120006554A (ko) * 2009-04-27 2012-01-18 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도
NO2686520T3 (https=) 2011-06-06 2018-03-17
EP2717870B1 (en) * 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
US10221198B2 (en) 2014-06-27 2019-03-05 Ecole Polytechnique Federale De Lausanne (Epfl) Preparation and medical use of triazenes
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Also Published As

Publication number Publication date
WO2010029577A2 (en) 2010-03-18
US8258119B2 (en) 2012-09-04
WO2010029577A3 (en) 2010-05-06
EP2324006A2 (en) 2011-05-25
KR20110063537A (ko) 2011-06-10
EP2324006B1 (en) 2014-08-13
CN102149703B (zh) 2014-09-10
CA2736732A1 (en) 2010-03-18
AU2009290365B2 (en) 2014-08-14
AU2009290365A1 (en) 2010-03-18
NZ591394A (en) 2013-03-28
CN102149703A (zh) 2011-08-10
IL211366A0 (en) 2011-04-28
JP2012502900A (ja) 2012-02-02
US20100068178A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0913485A2 (pt) medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
BRPI1006651A2 (pt) Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
PT2845604T (pt) Nova imunoterapia para vários tumores, incluindo cancro gastrointestinal e gástrico
BRPI0817677A2 (pt) Pó para bebida instantânea
DK2121731T3 (da) Peptidvacciner til cancere som udtrykker tumor-associerede antigener
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0808032A2 (pt) Processos para preparar hidroxipivalinaldeído e para preparar neopentil glicol.
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
PL3069728T3 (pl) Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
RU2448708C3 (ru) Противоопухолевое средство против рака щитовидной железы
PT2456889E (pt) Marcadores para o cancro do endométrio
FR2947435B1 (fr) Article cosmetique incluant une structure multicouche electrochromique.
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
PT2162149E (pt) Vacina para a prevenção da recaída do cancro da mama
BRPI0816150A2 (pt) genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
BRPI0924981A2 (pt) vacinas para câncer cervical.
EP2283862A4 (en) ANTITUMOR AGENT
DK2257301T3 (da) Immunterapi baseret på allogene cancerceller.
EP2147122A4 (en) ENZYMATIC TUMOR THERAPY
BRPI0922849A2 (pt) vacina para a prevenção de recorrência de câncer de mama
FI20075158L (fi) Muunneltuja hydroksipolymeerikonjugaatteja, joilla on syöpäsoluja tappava vaikutus
EP2502627A4 (en) ANTI CANCER AGENTS
FR2925235B1 (fr) Socle antivibratile multi-format

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.